Analytical Data
-
Gene name
STX1A
- Application
-
Alternative Names
STX-1A; HPC-1; STX1; P35-1; Neuron-specific antigen HPC-1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16623
-
Expression Region
Met1~Val255
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
STX1A, or Syntaxin 1A, is a pivotal protein involved in the process of synaptic vesicle fusion and neurotransmitter release in neurons. As a member of the Soluble N-ethylmaleimide-sensitive factor Attachment protein Receptor (SNARE) family, STX1A interacts with other SNARE proteins, such as SNAP-25 and VAMP, to form a functional membrane fusion complex crucial for effective synaptic transmission. Research has highlighted its role in various neurological processes and its implications in neurodegenerative diseases and synaptic disorders. Given the significance of synaptic signaling in the central nervous system, the study of STX1A and its recombinant protein form has garnered considerable attention. Researchers aim to elucidate its structural and functional properties, explore its interactions with other proteins, and understand its role in pathophysiological conditions. Moreover, STX1A's potential as a therapeutic target in treating neurological disorders underpins the necessity for advanced studies in this area. Recombinant STX1A proteins are utilized in assays to investigate protein interactions, vesicle trafficking dynamics, and the modulation of synaptic efficacy. Understanding STX1A at the molecular level could pave the way for novel interventions in treating synaptic dysfunctions, enhancing our ability to combat various cognitive and sensory impairments associated with neurological diseases. Overall, STX1A represents a critical area of research within molecular neuroscience, linking fundamental cellular mechanisms with clinical applications.
